Skip to main content

Advertisement

Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases

Arthritis Research & Therapy volume 11, Article number: R106 (2009) Cite this article

  • 6599 Accesses

  • 49 Citations

Abstract

Introduction

The majority of autoimmune diseases such as rheumatoid arthritis (RA) and autoimmune thyroid diseases (AITDs) are characterized by a striking female predominance superimposed on a predisposing genetic background. The role of extremely skewed X-chromosome inactivation (XCI) has been questioned in the pathogenesis of several autoimmune diseases.

Methods

We examined XCI profiles of females affected with RA (n = 106), AITDs (n = 145) and age-matched healthy women (n = 257). XCI analysis was performed by enzymatic digestion of DNA with a methylation sensitive enzyme (HpaII) followed by PCR of a polymorphic CAG repeat in the androgen receptor (AR) gene. The XCI pattern was classified as skewed when 80% or more of the cells preferentially inactivated the same X-chromosome.

Results

Skewed XCI was observed in 26 of the 76 informative RA patients (34.2%), 26 of the 100 informative AITDs patients (26%), and 19 of the 170 informative controls (11.2%) (P < 0.0001; P = 0.0015, respectively). More importantly, extremely skewed XCI, defined as > 90% inactivation of one allele, was present in 17 RA patients (22.4%), 14 AITDs patients (14.0%), and in only seven controls (4.1%, P < 0.0001; P = 0.0034, respectively). Stratifying RA patients according to laboratory profiles (rheumatoid factor and anti-citrullinated protein antibodies), clinical manifestations (erosive disease and nodules) and the presence of others autoimmune diseases did not reveal any statistical significance (P > 0.05).

Conclusions

These results suggest a possible role for XCI mosaicism in the pathogenesis of RA and AITDs and may in part explain the female preponderance of these diseases.

Introduction

It is postulated that the paternal and maternal antigens will be recognized by the immune system within the thymus, and T cells that have a high affinity for such antigens will be deleted by apoptosis [1–3]. The lack of exposure to a self-antigen in the thymus may lead to the presence of autoreactive T cells and increase the risk of autoimmunity [4]. In female mammalian cells, one of the two X-chromosomes is inactivated in early embryonic life [5]. Thus, females are mosaics for two cell populations, cells with either the paternal or the maternal X in the active form. X-chromosome choice is assumed to be random, and the result is generally 50% of cells expressing the paternal and the remaining 50% expressing the maternal genes [6]. A skewed X-chromosome inactivation (XCI) is a deviation from this ratio and is arbitrarily defined, for example, as a pattern where 80% or more of the cells inactivate the same X-chromosome [7]. This deviation may be the result of chance or genetic factors involved in the XCI or a selection process [8]. The existence of XCI in females offers a potential mechanism where by X-linked self-antigens may escape presentation in the thymus or in other peripheral sites that are involved in tolerance induction [9, 10]. This has become an attractive candidate mechanism for breakdown of self-tolerance in autoimmune diseases. An association between skewed XCI and scleroderma was recently reported [11]. A higher frequency of a skewed XCI pattern was found in patients affected with autoimmune thyroid diseases (AITDs) compared with healthy controls, indicating that skewed XCI may be associated with a predisposing factor for the development of AITDs [12–14]. It was therefore of interest to study if there is an association between skewed XCI and rheumatoid arthritis (RA) as a non-organ-specific and AITDs as an organ-specific autoimmune disease. We investigated the peripheral blood XCI patterns of 106 females affected with RA, 145 females affected with AITDs and 257 controls in the Tunisian and Turkish populations. Extremely skewed XCI was found in the blood samples of female patients affected with RA and AITDs supporting the role of skewed XCI in female predisposition to autoimmune diseases.

Materials and methods

Patients and controls

RA sample

One hundred and six Tunisian women affected with RA were recruited into the study. All patients fulfilled the 1987 American College of Rheumatology criteria for RA [15]. A rheumatologist university fellow (ZB) reviewed all clinical data. The mean age was 47.6 ± 13.4 (mean ± standard deviation (SD)) years. The duration of the symptoms was 15 ± 8.9 years. The mean age of diagnostic was 40.3 ± 12 years. Among 106 RA patients, 65 were rheumatoid factor (RF) positive (61.3%), 70 were anti-citrullinated protein/peptide antibodies (ACPA) positive (66%), 15 presented with nodules (14.1%), and 70 presented with erosive disease (66%). Fifteen patients had another accompanying autoimmune diseases such as Sjögren's syndrome, type 1 diabetes, or autoimmune thyroid diseases.

AITDs sample

One hundred and forty-five Tunisian women affected with AITDs were included in the study. There were a total of 58 patients with Graves' disease (GD) and 87 patients with Hashimoto's thyroiditis (HT), which include 40 patients with the goitrous form. The mean age was 46.5 ± 14.5 years for AITDs patients (49.3 ± 13 years in HT patients and 44.6 ± 14 years in GD patients). The duration of the symptoms was 7.5 ± 4.6 years among the AITDs patients (6.8 ± 4.8 years in HT patients and 7.2 ± 4 years in GD patients). The mean age of diagnosis was 37.9 ± 15.1 years. The diagnosis of GD was based on the presence of biochemical hyperthyroidism as indicated by a decrease of thyroid-stimulating hormone (TSH), an increase of T4 levels, and positive TSH receptor antibody, in association with diffuse goiter or the presence of exophthalmos. The diagnosis of HT was based on the presence of thyroid hormone replaced primary hypothyroidism, defined as a TSH level above the upper limits associated with positive titers of thyroid autoantibodies (anti-thyroglobulin and/or anti-thyroid peroxidase) and with or without a palpable goiter.

Control group

Caucasian females, comprised of 97 Tunisian and 160 Turkish healthy unrelated volunteers, served as controls in our studies. The mean (± SD) age at analysis was 43.5 ± 15.3 years and 35 ± 9.9 years for Tunisian and Turkish controls, respectively. There was no clinical evidence or family history of autoimmune disease and inflammatory joint disease.

All individuals (patients and controls) provided informed consent. The ethics committee of the Centre Hospitalo-Universitaire Hédi Chaker de Sfax, Tunisie, and the Bilkent University, Ankara, Turkey approved the study protocol.

Methods

Autoantibodies analysis

In AITDs patients, thyroid autoantibodies (anti-thyroglobulin and anti-thyroid peroxydase) were measured by ELISA and indirect immunofluorescence using commercially available kits (BINDAZYME™ Human EIA kits, Binding site Ltd, Birmingham, UK) with the respective normal ranges of 0 to 100 and 0 to 70 IU/mL.

The sera of RA patients obtained at the time of diagnosis were examined for RF by nephelometry and for ACPA by ELISA (second-generation test; Euro-Diagnostica, Arnhem, the Netherlands).

X-chromosome inactivation study

Genomic DNA was extracted from 10 ml of peripheral blood lymphocyte of patients and controls using standard methods [16]. Genotyping of a polymorphic site in the androgen receptor (AR) gene was performed and quantified to assess the XCI patterns as described [17]. The degree of skewing was estimated by an assay based on a methylation-sensitive HpaII restriction site located in exon 1 of the AR gene. This site is methylated on the inactive X, and unmethylated on the active X-chromosome. When the genomic DNA is cleaved with HpaII prior to PCR, only the methylated AR allele, which represents the inactive X-chromosome, is amplified. A polymorphic CAG repeat located within the amplified region is used to distinguish between the two alleles. For each patient and control two separate PCRs, with or without HpaII treatment, were performed using the same set of primers. Densitometric analysis of the alleles was performed at least twice for each sample using the MultiAnalyst version 1.1 software (Bio-rad, Hercules, California, USA). A corrected ratio (CrR) was calculated by dividing the ratio of the predigested sample (upper/lower allele) by the ratio of the non-predigested sample for normalization of the ratios that were obtained from the densitometric analyses. The use of CrR compensates for preferential amplification of the shorter allele when the number of PCR cycles increases [18]. A skewed population is defined as a cell population with greater than 80% expression of one of the AR alleles. This corresponds to CrR values of less than 0.33 or more than three.

Statistical methods

The results from control and test groups in XCI studies were compared by chi-squared test with Yate's correction. Fisher's exact test was used when one cell had an expected count of less than one, or more than 20% of the cells had an expected count of less than five. P values of 0.05 or less were considerate to be significant. Significance of P value was assessed using a Bonferroni correction at 5% (a P value less 0.05/9 = 0.005) is considered significant.

Results

XCI status was found to be informative in 76 of the 106 RA patients, 100 of the 145 AITDs patients and 170 of the 257 controls. Only those individuals whose alleles resolve adequately for densitometric analysis were included in the study. Skewed XCI (> 80% skewing) was observed in 26 of the 76 RA patients (34.2%), 26 of the 100 AITDs patients (26%), and 19 of the 170 controls (11.2%; P < 0.0001 and P = 0.0015). More importantly, the frequency of extremely skewed XCI (> 90% skewing) was 22.4% (17 of 76) in RA and 14.0% (14 of 100) in AITDs. These frequencies are both significantly higher than that of the control population, which is 4.1% (7 of 170; P < 0.0001 and P = 0.0034; Table 1). Subdividing AITDs patients according to clinical phenotype revealed that the frequency of skewed XCI was 35% (14 of 40, P = 0.0001) and 20% (12 of 60, P = 0.04) in GD and HT, respectively. Conversely, stratifying RA patients according to RF status, ACPA status, clinical manifestations (erosive disease and nodules) and others autoimmune diseases did not reveal a statistically significant difference (P > 0.05). Additionally, the comparison according to geographic origin showed a skewed XCI of RA patients compared with Tunisian controls (34.2% versus 19.5%; P = 0.03). However, difference was non-significant for AITDs subgroup (P > 0.05).

Table 1 Proportion of RA and AITDs patients and controls with skewed X-chromosome inactivation
Full size table

Extremely skewed XCI have been reported in 1 to 2% of 20 to 40 year old women, and in 2 to 4% of 55 to 72 year old women [19]. The data for RA and AITDs patients is strikingly bimodal, we plotted the distribution of the X inactivation profiles according to age. However, we did not observe a shift toward the skewed range in older patients and controls (Figures 1, 2 and 3). Characteristics of the RA and AITDs patients with skewed XCI are shown in Tables 2 and 3.

Figure 1
figure1

Distribution of X-chromosome inactivation patterns according to age in patients with rheumatoid arthritis.

Full size image
Figure 2
figure2

Distribution of X-chromosome inactivation patterns according to age in patients with autoimmune thyroid diseases.

Full size image
Figure 3
figure3

Distribution of X-chromosome inactivation patterns according to age control subjects. The control subjects were plotted according to geographic origin. Gray diamonds represent Tunisian controls and black diamonds represent Turkish controls.

Full size image
Table 2 Characteristics of the patients with rheumatoid arthritis and skewed X-chromosome inactivation
Full size table
Table 3 Characteristics of the patients with autoimmune thyroid diseases and skewed X-chromosome inactivation
Full size table

At the time of sample collection, 66 patients affected with RA were being treated with immunosuppressive therapies (methotrexate 10 to 15 mg once a week, n = 33; D-penicillamine 300 mg/day, n = 17; plaquenil 400 to 600 mg/day, n = 16). Among 76 informative patients, 46 were received immunosuppressive agents (61%). A major concern with the observed XCI patterns among RA patients was that concomitant immunosuppressive therapy could influence the results, as has been observed in feline hematopoietic cells [20]. Analysis of the data on XCI patterns according to immunosuppressive therapy did not reveal a statistically significant association between RA patients treated with methotrexate and controls (P = 0.52).

Discussion

The majority of human autoimmune diseases are characterized by female predominance. RA and AITDs have a female:male ratio of approximately 3:1 and 9:1, respectively [21]. Sex hormone influences have been suggested to explain this phenomenon because the X-chromosome contains a considerable number of sex and immune-related genes such as AR, IL2 receptor gamma chain, CD40 ligand and FOXP3 [22, 23]. These genes are essential in determining sex hormone levels and, more importantly, immune tolerance [24]. The contribution of genetics to sex differences in autoimmune diseases is currently unexplored. An alternative explanation for the female predominance has been recently proposed with the finding of an enhanced skewed XCI in peripheral bloods cells of female patients with autoimmune diseases [11–14]. The present study tests the hypothesis that skewed XCI would be more prevalent in females affected with autoimmune diseases than in female control individuals. Therefore, we simultaneously examined skewed XCI in 106 patients affected with RA and 145 patients affected with AITDs. The control group consisted of 170 female age-matched healthy individuals. We have demonstrated a significantly higher prevalence of extremely skewed XCI in blood cell of females affected with RA and AITDs compared with the control group (P < 0.0001; P = 0.0015, respectively), indicating a possible role of XCI in the etiology of autoimmune diseases, and in the female preponderance of RA and AITDs.

Skewed XCI was more commonly expected in peripheral blood mononuclear cells due to the very high rate of turnover of blood cells compared with other solid tissues [25]. Then, we have examined XCI in peripheral blood mononuclear cells of patients affected with RA and AITDs, and we found a higher incidence of skewed XCI in those patients. We also tested the relationship between XCI and AITDs phenotypes (GD and HT). A skewed XCI was associated with both GD and HT (P = 0.0001 and P = 0.04). Although, our results suggest the involvement of XCI in female predisposition to RA and AITDs, this hypothesis still to be confirmed in specific tissue, because our analysis was performed in DNA from blood, and this may not be a representative tissue for all autoimmune diseases [26, 27] and there may exist locally skewed XCI in the thymus. Moreover, this study can be complicated by existing differences in peripheral blood mononuclear cells constituents in RA versus healthy controls. The XCI distribution in both Tunisian and Turkish controls (Figure 3) according to age showed that 19.5% (9 of 46) have a skewed XCI in Tunisian controls which have a mean age of 43.5 years, whereas only 8% (10 of 124) in Turkish controls with a younger mean age (35 years). This result suggests the importance of age in the difference of XCI skewing.

Our results are in agreement with those reported by Ozçelik and colleagues on 110 unrelated Turkish female AITDs patients and 160 female controls that showed a greater proportion of a skewed pattern of XCI (34%) than in controls (8%; P < 0.0001) [13]. Indeed, supporting data have been reported by Brix and colleagues, which assessed that the prevalence of skewed XCI in female twins affected with AITDs was 34% but only 11% in controls (P = 0.003) and by Yin and colleagues (P = 0.004) [12–14]. Similar positive result was described in other autoimmune diseases such as scleroderma [11]. In addition, our results are the first report that describes a significant association between extremely skewed XCI and RA. Conversely, examination of XCI pattern of 58 Caucasian female patients affected with multiple sclerosis, 46 with systemic lupus erythematosus, 18 with juvenile RA and 45 with type 1 diabetes mellitus and 30 healthy women did not reveal skewed XCI patterns [28]. Despite extensive efforts of XCI analysis in different autoimmune diseases and populations, this hypothesis remains to be confirmed because there is no apparent autoimmunity directed against protein antigens encoded on the X chromosome and the fact that, for many autoimmune diseases, we found a female predominance in inbred mice models having two identical X chromosomes and therefore no 'foreign' antigens from the XCI [29].

In humans, it was reported that XCI process was genetically controlled by genes located on X chromosome [30]. It has also been suggested that genes on the X chromosome might show linkage with AITD and RA [31, 32]. Thus, the observed association between skewed XCI and AITD and RA is not causal but could be explained by linkage disequilibrium between mutation responsible for XCI process and AITD and RA susceptibility polymorphisms. In addition, numerous environmental risk factors such as tobacco smoking, hormones, diet, drugs, toxins and/or infections are important in determining whether an individual will develop autoimmune diseases [33]. In fact, environmental agents are able to amplify autoimmunity in genetically susceptible individuals and to break tolerance in genetically resistant individuals, there by increasing the risk of developing autoimmune diseases [34]. The interaction between genetic and environmental factors remains to be achieved in order to evaluate the involvement of each component in the development of such autoimmune reactions.

Conclusions

We suggest a possible role of XCI mosaicism in the pathogenesis of RA and AITDs. However, the process of XCI needs to be considered as a potential factor in the predominance of females in most autoimmune diseases. It would also be of interest first to study the XCI pattern in females affected with other autoimmune diseases and second to test the XCI patterns of many cell types.

Abbreviations

ACPA:

anti-citrullinated protein/peptide antibodies

AITDs:

autoimmune thyroid diseases

AR:

androgen receptor

CrR:

corrected ratio

ELISA:

enzyme-linked immunosorbent assay

GD:

Graves' disease

HT:

Hashimoto's thyroiditis

IL:

interleukin

PCR:

polymerase chain reaction

RA:

rheumatoid arthritis

RF:

Rheumatoid factor

SD:

standard deviation

TSH:

thyroid stimulating hormone

XCI:

X-chromosome inactivation.

References

  1. 1.

    Rougeulle C, Avner P: Controlling X-inactivation in mammals: what does the centre hold?. Semin Cell Dev Biol. 2003, 14: 331-340. 10.1016/j.semcdb.2003.09.014.

  2. 2.

    Kast RE: Predominance of autoimmune and rheumatic diseases in females. J Rheumatol. 1977, 4: 288-292.

  3. 3.

    Stewart JJ: The female × inactivation mosaic in systemic lupus erythematosus. Immunol Today. 1998, 19: 352-257. 10.1016/S0167-5699(98)01298-5.

  4. 4.

    Klein L, Klugmann M, Nave K-A, Tuohy VK, Kyewski B: Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nature Med. 2000, 6: 56-61. 10.1038/71540.

  5. 5.

    Puck JM, Stewart CC, Nussbaum RL: Maximum likelihood analysis of human T-cell X-chromosome inactivation patterns: normal women versus carriers of X-linked severe combined immunodeficiency. Am J Hum Genet. 1992, 50: 742-748.

  6. 6.

    Kristiansen M, Knudsen GPS, Bathum L, Naumova AK, Sorensen TI, Brix TH, Svendsen AJ, Christensen K, Kyvik KO, Orstavik KH: Twin study of genetic and aging effects on X-chromosome inactivation. Eur J Hum Genet. 2005, 13: 599-606. 10.1038/sj.ejhg.5201398.

  7. 7.

    Sharp A, Robinson D, Jacobs P: Age- and tissue-specific variation of X-chromosome inactivation ratios in normal women. Hum Genet. 2000, 107: 343-349. 10.1007/s004390000382.

  8. 8.

    Belmont JW: Genetic control of X inactivation and processes leading to X-inactivation skewing. Am J Hum Genet. 1996, 58: 1101-1108.

  9. 9.

    Laufer TM, Dekoning J, Markowitz JS, Lo D, Glimcher LH: Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature. 1996, 383: 81-85. 10.1038/383081a0.

  10. 10.

    Kyewski B, Derbinski J: Self-representation in the thymus: anextended view. Nat Rev Immunol. 2004, 4: 688-698. 10.1038/nri1436.

  11. 11.

    Ozbalkan Z, Bagislar S, Kiraz S, Akyerli CB, Ozer HT, Yavuz S, Birlik AM, Calguneri M, Ozcelik T: Skewed X-chromosome inactivation in blood cells of women with scleroderma. Arthritis Rheum. 2005, 52: 1564-1570. 10.1002/art.21026.

  12. 12.

    Brix TH, Knudsen GP, Kristiansen M, Kyvik K, Orstavik KH, Hegedus L: High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab. 2005, 90: 5949-5953. 10.1210/jc.2005-1366.

  13. 13.

    Ozcelik T, Uz E, Akyerli CB, Bagislar S, Mustafa CA, Gursoy A, Akarsu N, Toruner G, Kamel N, Gullu S: Evidence from autoimmune thyroiditis of skewed X-chromosome inactivation in female predisposition to autoimmunity. Eur J Hum Genet. 2006, 14: 791-797. 10.1038/sj.ejhg.5201614.

  14. 14.

    Yin X, Latif R, Tomer Y, Davies TF: Thyroid epigenetics: x-chromosome inactivation in patients with autoimmune thyroid disease. Ann N Y Acad Sci. 2007, 1110: 193-200. 10.1196/annals.1423.021.

  15. 15.

    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.

  16. 16.

    Kawazaki E: Sample preparation from blood, cells and other fluids. Origin of PCR protocols. A guide to methods and application. Edited by: Innis M, Gelffand D, Snisky G, White T. 1990, San Diego: Academic Press, 146-152.

  17. 17.

    Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X-chromosome inactivation. Am J Hum Genet. 1992, 51: 1229-1239.

  18. 18.

    Delforge M, Demuynck H, Vandenberghe P, Verhoef G, Zachée P, van Duppen V, Marijnen P, Berghe Van den H, Boogaerts MA: Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. Blood. 1995, 86: 3660-3667.

  19. 19.

    Knudsen GP, Pedersen J, Klingenberg O, Lygren I, Ãrstavik KH: Increased skewing of X-chromosome inactivation with age in both blood and buccal cells. Cytogenet Genome Res. 2007, 116: 24-28. 10.1159/000097414.

  20. 20.

    Abkowitz JL, Linenberger ML, Persik M, Newton MA, Guttorp P: Behavior of feline hematopoietic stem cells years after busulfan exposure. Blood. 1993, 82: 2096-2103.

  21. 21.

    Lockshin MD: Sex differences in autoimmune disease. Lupus. 2006, 15: 753-756. 10.1177/0961203306069353.

  22. 22.

    Chagnon P, Provost S, Belisle C, Bolduc V, Gingras M, Busque L: Age-associated skewing of X-inactivation ratios of blood cells in normal females: a candidate-gene analysis approach. Exp Hematol. 2005, 33: 1209-1214. 10.1016/j.exphem.2005.06.023.

  23. 23.

    Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, Modi WS, McBride OW, Leonard WJ: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell. 1993, 73: 147-157. 10.1016/0092-8674(93)90167-O.

  24. 24.

    HernA¡ndez-Molina G, Svyryd Y, Sánchez-Guerrero J, Mutchinick OM: The role of the X-chromosome in immunity and autoimmunity. Autoimmun Rev. 2007, 6: 218-222. 10.1016/j.autrev.2006.08.004.

  25. 25.

    Sharp A, Robinson D, Jacobs P: Age- and tissue-specific variation of X-chromosome inactivation ratios in normal women. Hum Genet. 2000, 107: 343-349. 10.1007/s004390000382.

  26. 26.

    Azofeifa J, Waldherr R, Cremer M: X-chromosome methylation ratios as indicators of chromosomal activity: evidence of intraindividual divergencies among tissues of different embryonal origin. Hum Genet. 1996, 97: 330-333. 10.1007/BF02185765.

  27. 27.

    Gale RE, Wheadon H, Boulos P, Linch DC: Tissue specificity of X-chromosome inactivation patterns. Blood. 1994, 83: 2899-2905.

  28. 28.

    Chitnis S, Monteiro J, Glass D, Apatoff B, Salmon J, Concannon P, Gregersen PK: The role of X-chromosome inactivation in female predisposition to autoimmunity. Arthritis Res. 2000, 2: 399-406. 10.1186/ar118.

  29. 29.

    Smith-Bouvier DL, Divekar AA, Sasidhar M, Du S, Tiwari-Woodruff SK, King JK, Arnold AP, Singh RR, Voskuhl RR: A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med. 2008, 12: 1099-1108. 10.1084/jem.20070850.

  30. 30.

    Naumova AK, Olien L, Bird LM, Smith M, Verner AE, Leppert M, Morgan K, Sapienza C: Genetic mapping of X-linked loci involved in skewing of X chromosome inactivation in the human. Eur J Hum Genet. 1998, 6: 552-562. 10.1038/sj.ejhg.5200255.

  31. 31.

    Tomer Y, Davies TF: Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev. 2003, 24: 694-717. 10.1210/er.2002-0030.

  32. 32.

    Shiozawa S, Hayashi S, Tsukamoto Y, Goko H, Kawasaki H, Wada T, Shimizu K, Yasuda N, Kamatani N, Takasugi K, Tanaka Y, Shiozawa K, Imura S: Identification of the gene loci that predispose to rheumatoid arthritis. Int Immunol. 1998, 10: 1891-1895. 10.1093/intimm/10.12.1891.

  33. 33.

    Edwards CJ, Cooper C: Early environmental factors and rheumatoid arthritis. Clin Exp Immunol. 2005, 143: 1-5. 10.1111/j.1365-2249.2005.02940.x.

  34. 34.

    Guarneri F, Benvenga S: Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2007, 14: 398-409.

Download references

Acknowledgements

This work was funded by Ministère de l'Enseignement Supérieur, Ministère de la Recherche Scientifique et de la Technologie (Tunisie). The International Centre for Genetic Engineering and Biotechnology ICGEB-CRP/TUR04-01, and Scientific and Technical Research Council of Turkey-TUBITAK-SBAG 3334 (to Dr. Ozcelik).

Author information

Affiliations

  1. Laboratoire de Génétique Moléculaire Humaine, Faculté de Médecine de Sfax, Avenue Majida Boulila, Sfax, 3029, Tunisie
    • Ghazi Chabchoub
    • , Abdellatif Maalej
    •  & Hammadi Ayadi
  2. Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, 06800, Turkey
    • Elif Uz
    • , Chigdem A Mustafa
    •  & Tayfun Ozcelik
  3. Unité de Bioinformatique, Centre de Biotechnologie de Sfax, Sfax, BP 3018, Tunisie
    • Ahmed Rebai
  4. Service d'Endocrinologie, Centre Hospitalo-universitaire Hédi Chaker de Sfax, Rue El-Ferdaous, Sfax, 3029, Tunisie
    • Mouna Mnif
  5. Service de Médecine Interne, Centre Hospitalo-universitaire Hédi Chaker de Sfax, Rue El-Ferdaous, Sfax, 3029, Tunisie
    • Zouheir Bahloul
  6. Osancor Biotech Inc, 31 Woodland Drive, Watford, Herts, WD17 3BY, UK
    • Nadir R Farid
  7. Institute for Materials Science and Nanotechnology (UNAM), Bilkent University, Ankara, 06800, Turkey
    • Tayfun Ozcelik
Authors
  1. Search for Ghazi Chabchoub in:
  2. Search for Elif Uz in:
  3. Search for Abdellatif Maalej in:
  4. Search for Chigdem A Mustafa in:
  5. Search for Ahmed Rebai in:
  6. Search for Mouna Mnif in:
  7. Search for Zouheir Bahloul in:
  8. Search for Nadir R Farid in:
  9. Search for Tayfun Ozcelik in:
  10. Search for Hammadi Ayadi in:

Corresponding author

Correspondence to Ghazi Chabchoub.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

GC carried out the molecular genetic study, performed the statistical analysis and wrote the manuscript. EU participated in the experimental work and the statistical analysis. AM participated in the design of the study and helped to draft the manuscript. AR participated in the statistical analysis. MM made pathological diagnosis and performed clinical data analyses. CAM participated in the molecular genetic study. ZB made pathological diagnosis, conducted sampling procedures, and performed clinical and rheumatological data analyses. TO conceived of the study, and participated in its design and coordination and helped to draft the manuscript. HA participated in the coordination of the study and revised the manuscript. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Authors’ original file for figure 3

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chabchoub, G., Uz, E., Maalej, A. et al. Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases. Arthritis Res Ther 11, R106 (2009). https://doi.org/10.1186/ar2759

Download citation

Keywords

  • Rheumatoid Arthritis
  • Rheumatoid Arthritis Patient
  • Androgen Receptor
  • Autoimmune Thyroid Disease
  • AITDs Patient

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us